ACR-368

· Acrivon Therapeutics

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for ACR-368, covering 2025-10-20 to 2026-03-24. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma [Phase 2]